Pyridostigmine ameliorates cardiac remodeling induced by myocardial infarction via inhibition of the transforming growth factor-β1/tgf-β1- activated kinase pathway

Journal of Cardiovascular Pharmacology

Volumn 63, Issue 5, 2014, Pages 412-420

  Lu, Yi ^a   Liu, Jin Jun ^a   Bi, Xue Yuan ^a   Yu, Xiao Jiang ^a   Kong, Shan Shan ^a   Qin, Fang Fang ^a   Zhou, Jun ^a   Zang, Wei Jin ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Fibrosis; Left ventricular remodeling; Pyridostigmine; TGF 1 TAK1

Indexed keywords

ATROPINE; COLLAGEN; PYRIDOSTIGMINE; TRANSFORMING GROWTH FACTOR BETA1; CHOLINESTERASE INHIBITOR; GELATINASE A; HYDROXYPROLINE; MAP KINASE KINASE KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FIBROSING ALVEOLITIS; HEART FUNCTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE; HEART VENTRICLE REMODELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; FIBROSIS; HEMODYNAMICS; MALE; METABOLISM; MYOCARDIAL INFARCTION; PATHOLOGY; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

ANIMALS; CHOLINESTERASE INHIBITORS; FIBROSIS; HEMODYNAMICS; HYDROXYPROLINE; MALE; MAP KINASE KINASE KINASES; MATRIX METALLOPROTEINASE 2; MYOCARDIAL INFARCTION; PYRIDOSTIGMINE BROMIDE; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1; VENTRICULAR REMODELING;

EID: 84900826595     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000062     Document Type: Article

References (49)

1. de Couto G, Ouzounian M, Liu PP. Early detection of myocardial dysfunction and heart failure. Nat Rev Cardiol. 2010;7:334-344.
2. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation. 2010;121:e46-e215.
3. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 1990;81:1161-1172.
4. Gonzalez A, Ravassa S, Beaumont J, et al. New targets to treat the structural remodeling of the myocardium. J Am Coll Cardiol. 2011;58: 1833-1843.
5. Kaur K, Zarzoso M, Ponce-Balbuena D, et al. TGF-beta1, released by myofibroblasts, differentially regulates transcription and function of sodium and potassium channels in adult rat ventricular myocytes. PLoS One. 2013;8:e55391.
6. Zhang D, Gaussin V, Taffet GE, et al. TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice. Nat Med. 2000;6:556-563.
7. Gu J, Liu X, Wang QX, et al. Angiotensin II increases CTGF expression via MAPKs/TGF-beta1/TRAF6 pathway in atrial fibroblasts. Exp Cell Res. 2012;318:2105-2115.
8. Li Q, Xu Y, Li X, et al. Inhibition of Rho-kinase ameliorates myocardial remodeling and fibrosis in pressure overload and myocardial infarction: role of TGF-beta1-TAK1. Toxicol Lett. 2012;211:91-97.
9. Rydlewska A, Jankowska EA, Ponikowska B, et al. Changes in autonomic balance in patients with decompensated chronic heart failure. Clin Auton Res. 2011;21:47-54.
10. Dalla VL, Barbic F, Galli A, et al. Favorable effects of carotid endarterectomy on baroreflex sensitivity and cardiovascular neural modulation: a 4-month follow-up. Am J Physiol Regul Integr Comp Physiol. 2013; 304:R1114-R1120.
11. Kong SS, Liu JJ, Hwang TC, et al. Tumour necrosis factor-alpha and its receptors in the beneficial effects of vagal stimulation after myocardial infarction in rats. Clin Exp Pharmacol Physiol. 2011;38:300-306.
12. Uemura K, Zheng C, Li M, et al. Early short-term vagal nerve stimulation attenuates cardiac remodeling after reperfused myocardial infarction. J Card Fail. 2010;16:689-699.
13. Schwartz PJ, De Ferrari GM, Sanzo A, et al. Long term vagal stimulation in patients with advanced heart failure: first experience in man. Eur J Heart Fail. 2008;10:884-891.
14. Nobrega AC, Loures DL, Pontes PV, et al. Cholinergic stimulation with pyridostigmine prevents the impairment in ventricular function during mental stress in coronary artery disease patients. Int J Cardiol. 2008; 125:418-421.
15. Nobrega AC, Carvalho AC, Santos KB, et al. Cholinergic stimulation with pyridostigmine blunts the cardiac responses to mental stress. Clin Auton Res. 1999;9:11-16.
16. Soares PP, Da NA, Ushizima MR, et al. Cholinergic stimulation with pyridostigmine increases heart rate variability and baroreflex sensitivity in rats. Auton Neurosci. 2004;113:24-31.
17. Haq S, Kilter H, Michael A, et al. Deletion of cytosolic phospholipase A2 promotes striated muscle growth. Nat Med. 2003;9:944-951.
18. Kobayashi M, Massiello A, Karimov JH, et al. Cardiac autonomic nerve stimulation in the treatment of heart failure. Ann Thorac Surg. 2013;96: 339-345.
19. Hauptman PJ, Schwartz PJ, Gold MR, et al. Rationale and study design of the increase of vagal tone in heart failure study: INOVATE-HF. Am Heart J. 2012;163:954-962.
20. Zhao M, He X, Bi XY, et al. Vagal stimulation triggers peripheral vascular protection through the cholinergic anti-inflammatory pathway in a rat model of myocardial ischemia/reperfusion. Basic Res Cardiol. 2013;108:345.
21. Sugimachi M, Uemura K, Kawada T, et al. Reduction of myocardial oxygen demand by controlling heart rate and hemodynamics simultaneously by novel circulatory model. Conf Proc IEEE Eng Med Biol Soc. 2011;2011:4297-4300.
22. Gao D, Zhang L, Dhillon R, et al. Dynasore protects mitochondria and improves cardiac lusitropy in Langendorff perfused mouse heart. PLoS One. 2013;8:e60967.
23. Manabe I, Shindo T, Nagai R. Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy. Circ Res. 2002;91: 1103-1113.
24. Diez J. Mechanisms of cardiac fibrosis in hypertension. J Clin Hypertens (Greenwich). 2007;9:546-550.
25. Xu X, Wan W, Powers AS, et al. Effects of exercise training on cardiac function and myocardial remodeling in post myocardial infarction rats. J Mol Cell Cardiol. 2008;44:114-122.
26. Brower GL, Levick SP, Janicki JS. Inhibition of matrix metalloproteinase activity by ACE inhibitors prevents left ventricular remodeling in a rat model of heart failure. Am J Physiol Heart Circ Physiol. 2007;292: H3057-H3064.
27. Cogni AL, Farah E, Minicucci MF, et al. Metalloproteinases-2 and -9 predict left ventricular remodeling after myocardial infarction. Arq Bras Cardiol. 2013;100:315-321.
28. Kuliczkowski W, Urbaniak J, Hallen J, et al. Matrix metalloproteinases and the activity of their tissue inhibitors in patients with ST-elevation myocardial infarction treated with primary angioplasty. Kardiol Pol. 2013;71:453-463.
29. Seeland U, Kouchi I, Zolk O, et al. Effect of ramipril and furosemide treatment on interstitial remodeling in post-infarction heart failure rat hearts. J Mol Cell Cardiol. 2002;34:151-163.
30. Wu D, Lin X, Bernloehr C, et al. Effects of a novel bradykinin B1 receptor antagonist and angiotensin II receptor blockade on experimental myocardial infarction in rats. PLoS One. 2012;7:e51151.
31. Yang CM, Lee IT, Hsu RC, et al. NADPH oxidase/ROS-dependent PYK2 activation is involved in TNF-alpha-induced matrix metalloproteinase-9 expression in rat heart-derived H9c2 cells. Toxicol Appl Pharmacol. 2013;272:431-442.
32. Schulz R. Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches. Annu Rev Pharmacol Toxicol. 2007;47:211-242.
33. Truter SL, Catanzaro DF, Supino PG, et al. Differential expression of matrix metalloproteinases and tissue inhibitors and extracellular matrix remodeling in aortic regurgitant hearts. Cardiology. 2009;113:161-168.
34. Adamcova M, Potacova A, Popelova O, et al. Cardiac remodeling and MMPs on the model of chronic daunorubicin-induced cardiomyopathy in rabbits. Physiol Res. 2010;59:831-836.
35. Xiao H, Zhang YY. Understanding the role of transforming growth factor-beta signalling in the heart: overview of studies using genetic mouse models. Clin Exp Pharmacol Physiol. 2008;35:335-341.
36. Chen YH, Liang CM, Chen CL, et al. Silibinin inhibits myofibroblast transdifferentiation in human tenon fibroblasts and reduces fibrosis in a rabbit trabeculectomy model. Acta Ophthalmol. 2013;91:e506-e515.
37. Kapur NK, Wilson S, Yunis AA, et al. Reduced endoglin activity limits cardiac fibrosis and improves survival in heart failure. Circulation. 2012; 125:2728-2738.
38. Calderone A, Murphy RJ, Lavoie J, et al. TGF-beta(1) and prepro-ANP mRNAs are differentially regulated in exercise-induced cardiac hypertrophy. J Appl Physiol. 2001;91:771-776.
39. Rahmutula D, Marcus GM, Wilson EE, et al. Molecular basis of selective atrial fibrosis due to overexpression of transforming growth factor-beta1. Cardiovasc Res. 2013;99:769-779.
40. Koitabashi N, Danner T, Zaiman AL, et al. Pivotal role of cardiomyocyte TGF-beta signaling in the murine pathological response to sustained pressure overload. J Clin Invest. 2011;121:2301-2312.
41. Matsumoto-Ida M, Takimoto Y, Aoyama T, et al. Activation of TGFbeta1- TAK1-p38 MAPK pathway in spared cardiomyocytes is involved in left ventricular remodeling after myocardial infarction in rats. Am J Physiol Heart Circ Physiol. 2006;290:H709-H715.
42. Wu A, Zhai J, Zhang D, et al. Effect of wenxin granule on ventricular remodeling and myocardial apoptosis in rats with myocardial infarction. Evid Based Complement Alternat Med. 2013;2013:967986.
43. Kakinuma Y, Tsuda M, Okazaki K, et al. Heart-specific overexpression of choline acetyltransferase gene protects murine heart against ischemia through hypoxia-inducible factor-1alpha-related defense mechanisms. J Am Heart Assoc. 2013;2:e4887.
44. Hill C, Wurfel A, Heger J, et al. Inhibition of AP-1 signaling by JDP2 overexpression protects cardiomyocytes against hypertrophy and apoptosis induction. Cardiovasc Res. 2013;99:121-128.
45. Rengo G, Cannavo A, Liccardo D, et al. Vascular Endothelial growth factor blockade prevents the beneficial effects of beta-Blocker therapy on cardiac function, angiogenesis and remodeling in heart failure. Circ Heart Fail. 2013;6:1259-1267.
46. Zhang XJ, Yang L, Zhao Q, et al. Induction of acetylcholinesterase expression during apoptosis in various cell types. Cell Death Differ. 2002;9:790-800.
47. Yu JG, Song SW, Shu H, et al. Baroreflex deficiency hampers angiogenesis after myocardial infarction via acetylcholine-alpha7-nicotinic ACh receptor in rats. Eur Heart J. 2013;34:2412-2420.
48. Tyagi E, Agrawal R, Nath C, et al. Cholinergic protection via alpha7 nicotinic acetylcholine receptors and PI3K-Akt pathway in LPS-induced neuroinflammation. Neurochem Int. 2010;56:135-142.
49. Setoguchi D, Yatsuki H, Sadahiro T, et al. Effects of a peripheral cholinesterase inhibitor on cytokine production and autonomic nervous activity in a rat model of sepsis. Cytokine. 2012;57:238-244.